Repligen (NASDAQ:RGEN) Stock Price Expected to Rise, Royal Bank of Canada Analyst Says

Repligen (NASDAQ:RGEN) had its target price increased by analysts at Royal Bank of Canada from $203.00 to $205.00 in a research note issued to investors on Friday,Benzinga reports. The firm presently has an “outperform” rating on the biotechnology company’s stock. Royal Bank of Canada’s price objective suggests a potential upside of 30.55% from the company’s previous close.

RGEN has been the topic of several other research reports. Canaccord Genuity Group boosted their target price on shares of Repligen from $165.00 to $170.00 and gave the stock a “hold” rating in a report on Friday. StockNews.com raised shares of Repligen from a “sell” rating to a “hold” rating in a report on Friday, January 3rd. Wolfe Research started coverage on shares of Repligen in a research report on Thursday, November 14th. They issued a “peer perform” rating on the stock. Canaccord Genuity Group started coverage on shares of Repligen in a research report on Tuesday, December 17th. They issued a “hold” rating and a $165.00 price target on the stock. Finally, HC Wainwright restated a “buy” rating and issued a $180.00 price target on shares of Repligen in a research report on Friday. Six equities research analysts have rated the stock with a hold rating and nine have given a buy rating to the company’s stock. According to MarketBeat, Repligen has a consensus rating of “Moderate Buy” and an average target price of $183.36.

Repligen Price Performance

Shares of RGEN stock traded down $5.65 during mid-day trading on Friday, hitting $157.02. The company had a trading volume of 239,254 shares, compared to its average volume of 592,207. Repligen has a 52-week low of $113.50 and a 52-week high of $203.13. The stock’s 50 day moving average price is $155.17 and its 200-day moving average price is $148.81. The company has a debt-to-equity ratio of 0.26, a current ratio of 10.44 and a quick ratio of 8.76. The company has a market capitalization of $8.80 billion, a P/E ratio of -424.14, a P/E/G ratio of 4.23 and a beta of 0.99.

Repligen (NASDAQ:RGEN) last released its earnings results on Thursday, February 20th. The biotechnology company reported $0.44 EPS for the quarter, topping the consensus estimate of $0.41 by $0.03. Repligen had a negative net margin of 3.36% and a positive return on equity of 3.90%. The firm had revenue of $167.55 million for the quarter, compared to the consensus estimate of $167.58 million. Equities research analysts forecast that Repligen will post 1.54 earnings per share for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the company. Price T Rowe Associates Inc. MD increased its position in Repligen by 11.6% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 7,136,054 shares of the biotechnology company’s stock valued at $1,027,165,000 after acquiring an additional 743,815 shares during the last quarter. Vanguard Group Inc. grew its holdings in shares of Repligen by 1.1% in the fourth quarter. Vanguard Group Inc. now owns 5,101,090 shares of the biotechnology company’s stock worth $734,251,000 after purchasing an additional 56,723 shares during the last quarter. Champlain Investment Partners LLC grew its holdings in shares of Repligen by 8.6% in the fourth quarter. Champlain Investment Partners LLC now owns 1,543,530 shares of the biotechnology company’s stock worth $222,176,000 after purchasing an additional 122,595 shares during the last quarter. Alliancebernstein L.P. grew its holdings in shares of Repligen by 23.4% in the fourth quarter. Alliancebernstein L.P. now owns 1,010,896 shares of the biotechnology company’s stock worth $145,508,000 after purchasing an additional 191,439 shares during the last quarter. Finally, Conestoga Capital Advisors LLC grew its holdings in shares of Repligen by 0.7% in the fourth quarter. Conestoga Capital Advisors LLC now owns 947,582 shares of the biotechnology company’s stock worth $136,395,000 after purchasing an additional 6,872 shares during the last quarter. Institutional investors own 97.64% of the company’s stock.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.